Saccharomyces boulardii prevented the development of high counts of Clostridium difficile, high titers of toxin B, and positive latex agglutination tests after cessation of vancomycin treatment for hamsters. The protocol used was designed to simulate relapse of human C. difficile-associated colitis. S. boulardii was protective in this model.
Saccharomyces boulardii prevented the development of high counts of Clostridium difficile, high titers of toxin B, and positive latex agglutination tests after cessation of vancomycin treatment for hamsters. The protocol used was designed to simulate relapse of human C. difficile-associated colitis. S. boulardii was protective in this model.
Vancomycin is commonly used to treat Clostridium difficile-induced pseudomembranous colitis (PMC), and while therapy is usually successful, relapse of PMC is common (10, 16, 17, 23) , with rates of 11 to 50% previously reported (5, 9, 22, 25) . Browne et al. (6) and Bartlett et al. (4, 5) have shown that daily administration of vancomycin to hamsters protects them from clindamycin-induced death; however, once treatment is stopped, they succumb to cecitis caused by overgrowth of toxigenic C. difficile. We modified this procedure to obtain a reproducible animal model of the relapse of PMC that occurs in humans after cessation of vancomycin treatment. This model was used to study the effect of Saccharomyces boulardii, a nonpathogenic yeast which had previously been shown to decrease C. difficileassociated cecitis and death (13, 19) . We hypothesized that it could decrease the rate of PMC relapse after cessation of vancomycin treatment.
Hamsters were given a single, potentially lethal oral dose of clindamycin (10 mg/kg), after which they were protected from cecitis by a vancomycin solution (0.35 mg/ml) as the source of drinking water for 10 days. Of the 18 animals given only water, 13 succumbed to cecitis within 6 days of the dose of clindamycin; there were no deaths among the vancomycin-treated animals (data not shown). It was found that the development of high counts (>106) of C. difficile after vancomycin treatment was variable. Therefore, a toxigenic strain of C. difficile from a moribund, unprotected hamster was isolated, and a washed-cell suspension (-103 CFU) was used to orally inoculate all animals every 48 h after stopping vancomycin treatment. At the end of the 10-day vancomycin treatment, some animals were given a 5% suspension (5 x 108 CFU/ml) of S. boulardii (made fresh daily) as a source of drinking water (19) , while the others received only water.
At designated times ( With this model, animals reproducibly became infected with C. difficile (>105 CFU) after vancomycin treatment. Significant differences between C. difficile counts for controls and treated animals were observed for those time points at which the average log counts were greater than seven for controls. The highest average C. difficile log count for yeast-treated animals was 6.6. The most striking effect of yeast treatment was the decrease in toxin B and in the number of animals that were LAT positive (Table 1) . Of the yeast-treated animals tested in all experiments, only 2 of 66 (3%) were positive in the LAT, and 2 of 73 (3%) were positive for toxin B. In contrast, 22 of 66 (33%) control animals were positive in the LAT, and 37 of 73 (51%) were positive for toxin B. The original purpose of the LAT was to detect toxin A (enterotoxin); however, the specificity of the LAT has been questioned (12) . Recent evidence has shown that the LAT reacts with an as-yet-uncharacterized protein of low molecular weight and not with the enterotoxin. This protein is associated with C. difficile and toxin B and may be of some use for detection purposes (3, 14) .
Further work is needed to determine whether the sharp reduction in toxin titers is a result of the lower C. difficile counts in yeast-treated hamsters or a direct action of S. boulardii on the toxins. While these experiments were not designed to measure mortality as an endpoint, some hamsters died from diarrhea and cecitis before the time of sacrifice (Table 1) . After vancomycin treatment was stopped, 18 of 120 animals receiving water died, along with 1 of 117 animals receiving the yeast.
Our efforts have focused on modalities to prevent the antibiotic-mediated decline of resistance of the gut ecosystem ("colonization resistance" [21] ) to overgrowth by C. difficile. We propose that S. boulardii has potential as an exogenously administered agent for maintaining colonization resistance during antibiotic therapy because this yeast (i) is not affected by antibacterial antibiotics or sulfonamides, (ii) is nonpathogenic, (iii) has demonstrated antagonistic activity (in vitro and in vivo) against various bacterial pathogens (7) and Candida spp. (7, 8, 15) , and (iv) has been shown to decrease antibiotic-associated diarrhea in clinical trials in humans (2, 11, 18) . Previous work (13, 19) has demonstrated a decrease in mortality for S. boulardii-treated hamsters given clindamycin (an animal model for human PMC). The present study employed a protocol designed to simulate the relapse frequently observed after vancomycin treatment of human PMC. The results confirmed our hypothesis that S. boulardii administration would help prevent extensive overgrowth of C. difficile. An unexpected finding was the near absence of C. difficile toxins in treated animals. Intestinal colonization resistance enhanced by S. boulardii should be tested as a modality for diminishing the high incidence of PMC relapse after vancomycin treatment for humans.
